DETAILED NOTES ON SITUS JUDI MBL77

Aside from ibrutinib, people with M-CLL, devoid of TP53 aberrations and match sufficient to tolerate FCR therapy, should still be great candidates for that latter, Using the advantage being that this treatment is often done in six months whilst ibrutinib has to be taken indefinitely. This option could be especially valuable for non-compliant people